Pharmaceutical manufacturing across Asia is entering a high-performance phase, defined by scale, speed, and advanced production capabilities. The sector is rapidly moving beyond traditional output, integrating contract development and manufacturing, biologics processing, and precision formulation services. Smart manufacturing environments, powered by automation and real-time data analytics, are improving throughput while maintaining stringent quality and compliance standards expected in global markets.
The regional market continues to expand at a strong pace, supported by rising healthcare demand, expanding industrial capacity, and competitive cost structures. Asia has become a critical production hub, balancing high-volume generics manufacturing with increasing investment...
Company Logo |
Company Name |
Company Management |
Company Description |
|---|---|---|---|
 |
Astellas Pharma | Naoki Okamura, CEO | As a global life sciences company committed to turning innovative science into value for patients, the company provides transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. |
 |
Celltrion | Seo Jin-seok, CEO | The company specializes in the development, manufacturing, and commercialization of biosimilars and innovative biologics, serving global markets, and its product portfolio features several key biosimilars, including Remsima, Truxima, Herzuma, Yuflyma, and Vegzelma, among others |
 |
Chugai Pharmaceutical | Osamu Okuda, CEO | The firm specializes in the research, development, and commercialization of innovative drugs, particularly therapeutic antibodies, with a strong emphasis on oncology and immunology, and its portfolio includes monoclonal antibodies such as Rituxan and Herceptin, along with anti-cancer agents like Xeloda and Avastin |
 |
Otsuka Holdings | Makoto Inoue, CEO | The company is focused on pharmaceuticals, nutraceuticals, consumer products, and other healthcare-related businesses, and develops and sells a range of products targeting various health conditions, including mental health, cardiovascular issues, and infectious diseases |
 |
CSL | Gordon Naylor, Interim CEO | The company specializes in researching, developing, manufacturing, and marketing therapies for rare and serious diseases, with a product portfolio that includes blood plasma derivatives, vaccines, antivenoms, and cell culture reagents |
 |
Samsung Biologics | John Rim, CEO | The company specializes in providing comprehensive biologics services, including late-stage discovery, cell line development, cGMP manufacturing, and regulatory support, with a focus on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), mRNA vaccines, and biosimilars |
 |
Daiichi Sankyo | Hiroyuki Okuzawa, CEO | The company develops a range of innovative pharmaceutical products across various therapeutic areas, with notable offerings including Prasugrel, LIXIANA, ENHERTU, and VANFLYTA |
 |
Sun Pharma | Kirti Ganorkar, CEO | The company’s portfolio includes generics, branded generics, specialty products, and active pharmaceutical ingredients (APIs), covering a wide range of therapeutic areas such as psychiatry, neurology, cardiology, and dermatology |
 |
Jiangsu Hengrui Pharmaceuticals | Sun Piaoyang, Chairperson | The company specializes in innovative drug research, development, manufacturing, and distribution across key therapeutic areas, including oncology, cardiovascular, metabolic diseases, immunology, respiratory, and neuroscience, with a oncology portfolio featuring 14 approved drugs targeting solid tumors and hematology |
 |
Takeda Pharmaceutical | Christophe Weber, CEO | The company produces small molecules, biologics, vaccines, and plasma-derived therapies, and maintains a specialized portfolio across gastroenterology, rare diseases, oncology, neuroscience, and plasma-derived therapies |
We use cookies to ensure you get the best experience on our website. Read more...